CRL3-SPOP泛素连接酶复合物通过负调控MyD88/NF-κB信号抑制弥漫大B细胞淋巴瘤生长
本研究揭示SPOP作为CUL3型E3泛素连接酶复合物的衔接蛋白,可结合MyD88并诱导其非降解性泛素化,从而阻断Myddosome组装及下游NF-κB活化。SPOP在包括DLBCL在内的部分淋巴系统恶性肿瘤中发生突变,突变体丧失结合MyD88及抑制NF-κB的能力;而DLBCL相关的MyD88突变体逃避SPOP介导的泛素化,对NF-κB激活作用强于野生型MyD88。SPOP在体外和体内均通过抑制MyD88/NF-κB信号抑制DLBCL细胞生长,发挥抑癌作用。
要点
- SPOP通过识别MyD88的非典型结合基序诱导其非降解性泛素化,阻断Myddosome组装和NF-κB活化。
- 淋巴系统恶性肿瘤相关的SPOP突变体结合MyD88及抑制NF-κB的能力受损。
- DLBCL相关的MyD88突变体逃避SPOP介导的泛素化,对NF-κB激活强于野生型。
核心结论
- SPOP在DLBCL中发挥抑癌作用,通过负调控MyD88/NF-κB信号抑制肿瘤生长。
- SPOP-MyD88结合界面突变可破坏该调控轴,促进DLBCL中MyD88/NF-κB异常激活和细胞生长。
研究设计与样本
- 基础研究,探讨SPOP对MyD88/NF-κB信号的调控机制及其在DLBCL中的作用。
- 使用DLBCL细胞系进行体外生长实验及体内肿瘤异种移植实验。
主要发现
- SPOP结合MyD88并诱导其非降解性泛素化,阻断Myddosome组装和下游NF-κB活化。
- SPOP在包括DLBCL在内的部分淋巴系统恶性肿瘤中突变,突变体结合MyD88和抑制NF-κB的能力受损。
- DLBCL相关的SPOP结合缺陷型MyD88突变体逃避SPOP介导的泛素化,对NF-κB激活强于野生型MyD88。
- SPOP通过抑制MyD88/NF-κB信号在体外抑制DLBCL细胞生长,并在体内抑制肿瘤异种移植生长。
临床怎么用
- 提示SPOP-MyD88调控轴可作为DLBCL中MyD88/NF-κB信号异常激活的潜在干预靶点。
- 对于MyD88野生型DLBCL,SPOP功能缺失可能是NF-κB异常激活的替代机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent oncogenic mutations of MyD88 have been identified in a variety of lymphoid malignancies. Gain-of-function mutations of MyD88 constitutively activate downstream NF-κB signaling pathways, resulting in increased cellular proliferation and survival. However, whether MyD88 activity can be aberrantly regulated in MyD88-wild-type lymphoid malignancies remains poorly understood. SPOP is an adaptor protein of CUL3-based E3 ubiquitin ligase complex and frequently mutated genes in prostate and endometrial cancers. In this study, we reveal that SPOP binds to and induces the nondegradative ubiquitination of MyD88 by recognizing an atypical SPOP-binding motif in MyD88. This modification blocks Myddosome assembly and downstream NF-κB activation. SPOP is mutated in a subset of lymphoid malignancies, including diffuse large B-cell lymphoma (DLBCL). Lymphoid malignancies-associated SPOP mutants exhibited impaired binding to MyD88 and suppression of NF-κB activation. The DLBCL-associated, SPOP-binding defective mutants of MyD88 escaped from SPOP-mediated ubiquitination, and their effect on NF-κB activation is stronger than that of wild-type MyD88. Moreover, SPOP suppresses DLBCL cell growth in vitro and tumor xenograft in vivo by inhibiting the MyD88/NF-κB signaling. Therefore, SPOP acts as a tumor suppressor in DLBCL. Mutations in the SPOP-MyD88 binding interface may disrupt the SPOP-MyD88 regulatory axis and promote aberrant MyD88/NF-κB activation and cell growth in DLCBL.
引用
- Jin X, Shi Q, Li Q, et al. CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling. Leukemia. 2019. PMID: 31776466. doi:10.1038/s41375-019-0661-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。